Randomized, Double-blind, Placebo-controlled, Dose Escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of IOA-289 in Healthy Male Volunteers
Latest Information Update: 24 Mar 2025
At a glance
- Drugs IOA 289 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors iOnctura
Most Recent Events
- 20 Mar 2025 Status changed from recruiting to completed.
- 04 Dec 2024 Planned End Date changed from 20 Dec 2024 to 20 Dec 2025.
- 04 Dec 2024 Planned primary completion date changed from 7 Dec 2024 to 7 Jun 2025.